Vol 26, No 6 (2019)
Original articles — Interventional cardiology
Published online: 2018-07-13

open access

Page views 2197
Article views/downloads 813
Get Citation

Connect on Social Media

Connect on Social Media

Effect of intracoronary adenosine on ergonovine-induced vasoconstricted coronary arteries

Jun-Hyok Oh1, Seunghwan Song1, Changhoon Kim1, Jinhee Ahn1, Jin Sup Park1, Hye Won Lee1, Jung Hyun Choi1, Han Cheol Lee1, Kwang Soo Cha1, Taek Jong Hong1
Pubmed: 30009375
Cardiol J 2019;26(6):653-660.


Background: This study aimed to evaluate the effect of adenosine on epicardial coronary artery diameter
during ergonovine provocation testing.
Methods: A total of 158 patients who underwent an ergonovine provocation test with intracoronary
adenosine injection between 2011 and 2014 were selected. Patients were divided into four groups based
on the severity of percent diameter stenosis following intracoronary ergonovine administration: Group 1,
induced spasm < 50%; Group 2, 50–89%; Group 3, 90–99%; and Group 4, total occlusion.
Results: Spasm positivity was observed in 44 (27.8%) cases in the study population (mean age, 57.4 ±
± 10.7 years). Intracoronary adenosine increased the diameter of the ergonovine-induced epicardial
artery by 0.51 ± 0.31 mm, 0.73 ± 0.39 mm, 0.44 ± 0.59 mm, and 0.01 ± 0.04 mm in Groups 1, 2, 3,
and 4, respectively. Subsequent administration of nitroglycerin further increased vessel diameter by
0.49 ± 0.28 mm, 0.93 ± 0.68 mm, 2.11 ± 1.25 mm, and 2.23 ± 0.69 mm in Groups 1, 2, 3, and 4,
respectively. The ratios of adenosine-induced diameter to reference diameter were significantly lower
in patients with spasm positive results (0.68 [0.59–0.76] vs. 0.18 [0.00–0.41], p < 0.001 in the study
population; 0.60 [0.54–0.67] vs. 0.40 [0.27–0.44], p < 0.001 in Group 2) with the best cut-off value of
0.505 (sensitivity 0.955, specificity 0.921).
Conclusions: Intracoronary administration of adenosine dilated the ergonovine-induced vasoconstricted
epicardial coronary artery. The ratio of adenosine-induced diameter to reference diameter was
significantly lower in patients with spasm positive results.

Article available in PDF format

View PDF Download PDF file


  1. Stern S, Bayes de Luna A. Coronary artery spasm: a 2009 update. Circulation. 2009; 119(18): 2531–2534.
  2. Radico F, Cicchitti V, Zimarino M, et al. Angina pectoris and myocardial ischemia in the absence of obstructive coronary artery disease: practical considerations for diagnostic tests. JACC Cardiovasc Interv. 2014; 7(5): 453–463.
  3. Im SIl, Choi WG, Rha SW, et al. Significant response to lower acetylcholine dose is associated with worse clinical and angiographic characteristics in patients with vasospastic angina. Korean Circ J. 2013; 43(7): 468–473.
  4. Yildirim AB, Basarici I, Kucuk M. Recurrent ventricular arrhythmias and myocardial infarctions associated with cocaine induced reversible coronary vasospasm. Cardiol J. 2010; 17(5): 512–517.
  5. Yamagishi M, Miyatake K, Tamai J, et al. Intravascular ultrasound detection of atherosclerosis at the site of focal vasospasm in angiographically normal or minimally narrowed coronary segments. J Am Coll Cardiol. 1994; 23(2): 352–357.
  6. Beltrame JF, Sasayama S, Maseri A. Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. J Am Coll Cardiol. 1999; 33(6): 1442–1452.
  7. Zaya M, Mehta PK, Merz CN. Provocative testing for coronary reactivity and spasm. J Am Coll Cardiol. 2014; 63(2): 103–109.
  8. Shin DIl, Baek SH, Her SHo, et al. The 24-month prognosis of patients with positive or intermediate results in the intracoronary ergonovine provocation test. JACC Cardiovasc Interv. 2015; 8(7): 914–923.
  9. Curry RC, Pepine CJ, Sabom MB, et al. Similarities of ergonovine-induced and spontaneous attacks of variant angina. Circulation. 1979; 59(2): 307–312.
  10. Schroeder JS, Bolen JL, Quint RA, et al. Provocation of coronary spasm with ergonovine maleate. New test with results in 57 patients undergoing coronary arteriography. Am J Cardiol. 1977; 40(4): 487–491.
  11. Eltzschig HK. Adenosine: an old drug newly discovered. Anesthesiology. 2009; 111(4): 904–915.
  12. Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014; 63(23): 2503–2509.
  13. Layland J, Carrick D, Lee M, et al. Adenosine: physiology, pharmacology, and clinical applications. JACC Cardiovasc Interv. 2014; 7(6): 581–591.
  14. Kim J, Kim C, Kim J, et al. The eff ect of intracoronary administration of ergonovine on the contralateral coronary artery in a provocation test for the diagnosis of variant angina. Acta Cardiol. 2017; 69(6): 628–636.
  15. JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013). Circ J. 2014; 78(11): 2779–2801.
  16. McGeoch RJ, Oldroyd KG. Pharmacological options for inducing maximal hyperaemia during studies of coronary physiology. Catheter Cardiovasc Interv. 2008; 71(2): 198–204.
  17. Feliciano L, Henning RJ. Coronary artery blood flow: physiologic and pathophysiologic regulation. Clin Cardiol. 1999; 22(12): 775–786.
  18. DeFily DV, Chilian WM. Coronary microcirculation: autoregulation and metabolic control. Basic Res Cardiol. 1995; 90(2): 112–118.
  19. Liao JC, Kuo L. Interaction between adenosine and flow-induced dilation in coronary microvascular network. Am J Physiol. 1997; 272(4 Pt 2): H1571–H1581.
  20. Shiode N, Morishima N, Nakayama K, et al. Flow-mediated vasodilation of human epicardial coronary arteries: effect of inhibition of nitric oxide synthesis. J Am Coll Cardiol. 1996; 27(2): 304–310.
  21. Lupi A, Buffon A, Finocchiaro ML, et al. Mechanisms of adenosine-induced epicardial coronary artery dilatation. Eur Heart J. 1997; 18(4): 614–617.
  22. Drexler H, Zeiher AM, Wollschläger H, et al. Flow-dependent coronary artery dilatation in humans. Circulation. 1989; 80(3): 466–474.
  23. Cooke JP, Rossitch E, Andon NA, et al. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest. 1991; 88(5): 1663–1671.
  24. Schwartz JS, Baran KW, Bache RJ. Effect of stenosis on exercise-induced dilation of large coronary arteries. Am Heart J. 1990; 119(3 Pt 1): 520–524.
  25. Chu A, Chambers DE, Lin CC, et al. Effects of inhibition of nitric oxide formation on basal vasomotion and endothelium-dependent responses of the coronary arteries in awake dogs. J Clin Invest. 1991; 87(6): 1964–1968.
  26. Kugiyama K, Yasue H, Okumura K, et al. Nitric oxide activity is deficient in spasm arteries of patients with coronary spastic angina. Circulation. 1996; 94(3): 266–271.